Maintenance immunotherapy with low-dose of interleukin-2 (IL-2) and 13-cis-retinoic acid (RA) in patients with metastatic colorectal cancer (MCRC) showing a clinical benefit (CB) from chemotherapy. results of a multicenter phase II study